Ra Capital Management, L.P. Buys 391,019 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. purchased 391,019 shares of the company’s stock in a transaction that occurred on Friday, June 12th. The shares were purchased at an average price of $8.57 per share, with a total value of $3,351,032.83. Following the completion of the transaction, the director directly owned 16,622,736 shares of the company’s stock, valued at $142,456,847.52. This represents a 2.41% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, June 16th, Ra Capital Management, L.P. purchased 124,893 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $8.89 per share, with a total value of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. purchased 15,414 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $8.99 per share, with a total value of $138,571.86.
• On Thursday, June 11th, Ra Capital Management, L.P. acquired 548,580 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $7.91 per share, for a total transaction of $4,339,267.80.
• On Wednesday, June 10th, Ra Capital Management, L.P. acquired 103 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $7.00 per share, for a total transaction of $721.00.
• On Tuesday, June 9th, Ra Capital Management, L.P. acquired 479,039 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $6.91 per share, for a total transaction of $3,310,159.49.
• On Monday, May 11th, Ra Capital Management, L.P. acquired 6,510,416 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $11.52 per share, for a total transaction of $74,999,992.32.

Artiva Biotherapeutics Stock Performance

NASDAQ ARTV opened at $9.94 on Thursday. The stock’s fifty day moving average is $9.07 and its two-hundred day moving average is $6.28. The firm has a market capitalization of $245.72 million, a P/E ratio of -2.81 and a beta of 2.38. Artiva Biotherapeutics, Inc. has a fifty-two week low of $1.47 and a fifty-two week high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). As a group, sell-side analysts forecast that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. HC Wainwright upped their price target on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. Wedbush upped their price target on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. Finally, Needham & Company LLC reissued a “buy” rating and set a $41.00 target price on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $39.00.

Hedge Funds Weigh In On Artiva Biotherapeutics

Several hedge funds have recently bought and sold shares of the company. Citadel Advisors LLC lifted its stake in Artiva Biotherapeutics by 419.3% during the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after acquiring an additional 644,658 shares in the last quarter. BNP Paribas Financial Markets raised its position in Artiva Biotherapeutics by 14,463.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after purchasing an additional 117,733 shares in the last quarter. Renaissance Technologies LLC raised its position in Artiva Biotherapeutics by 46.8% in the 4th quarter. Renaissance Technologies LLC now owns 116,200 shares of the company’s stock valued at $498,000 after purchasing an additional 37,053 shares in the last quarter. Marshall Wace LLP acquired a new stake in Artiva Biotherapeutics in the 4th quarter valued at about $341,000. Finally, Jane Street Group LLC acquired a new stake in Artiva Biotherapeutics in the 2nd quarter valued at about $67,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.